Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
暂无分享,去创建一个
Ruth Ladenstein | Jérôme Couturier | Victoria Castel | Alberto Garaventa | Penelope Brock | P. Ambros | L. Boni | A. Cañete | J. Couturier | A. Di Cataldo | J. Michon | V. Mosseri | R. Ladenstein | B. De Bernardi | A. Garaventa | P. Brock | Andrea Di Cataldo | D. Valteau‐Couanet | Dominique Valteau-Couanet | Jean Michon | V. Castel | D. Plantaz | H. Rubié | Bénédicte Brichard | K. Holmes | C. Munzer | C. Márquez | M. Gerrard | B. Brichard | A. Pearson | Adela Canete | Keith Holmes | Mary Gerrard | Hervé Rubie | Caroline Munzer | Bruno De Bernardi | Peter Ambros | Véronique Mosseri | Andrew D J Pearson | Catalina Marquez | Dominique Plantaz | Luca Boni
[1] D. Frappaz,et al. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease: A prospective study of 42 patients‐‐Results of the NBL 90 study of the French Society of Pediatric Oncology , 1996, Cancer.
[2] P. Froehlich,et al. Long‐term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: Results of the SFOP NBL90 study , 2005, Pediatric blood & cancer.
[3] A. Donfrancesco,et al. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Leverger,et al. Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP). , 1998, British Journal of Cancer.
[5] W. Gerald,et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] O. Delattre,et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] F. Speleman,et al. Quality assessment of genetic markers used for therapy stratification. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Giovanni Cecchetto,et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Gudrun Schleiermacher,et al. Accumulation of segmental alterations determines progression in neuroblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] B. Korf,et al. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Donfrancesco,et al. Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Frappaz,et al. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique. , 2001, Medical and pediatric oncology.
[13] F. Berthold,et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Giovanni Cecchetto,et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Bernard,et al. Evaluation of the role of surgery in 130 patients with neuroblastoma. , 1985, Journal of pediatric surgery.
[16] J Pritchard,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Stram,et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Ruth Ladenstein,et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Bergeron,et al. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy , 2003, British Journal of Cancer.
[20] R. Arceci. Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97 , 2009 .
[21] A. Evans,et al. Factors influencing survival of children with nonmetastatic neuroblastoma , 1976, Cancer.
[22] J. Shuster,et al. A population-based study of neuroblastoma incidence, survival, and mortality in North America. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.